Outcome of Patients with Acute Myocardial Infarction Who Are Ineligible for Thrombolytic Therapy
- 1 August 1991
- journal article
- clinical trial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 115 (3) , 173-177
- https://doi.org/10.7326/0003-4819-115-3-173
Abstract
To determine what proportion of patients with acute myocardial infarction are not eligible for thrombolytic therapy and to assess their natural history. Retrospective chart review. A large community-based hospital. All patients with acute myocardial infarction hospitalized during a 27-month period. Of 1471 patients with acute myocardial infarction, 230 (16%) received thrombolytic therapy according to the protocol and an additional 97 (7%) received nonprotocol thrombolytic therapy, primary coronary balloon angioplasty, or both because of contraindications. The other 1144 patients (78%) did not receive reperfusion therapy. The patients who did not receive thrombolytic therapy were older, more likely to be women, and more likely to have a history of hypertension, previous myocardial infarction, or chronic angina (all comparisons, P less than 0.002). An average of 1.9 reasons for exclusion were identified per patient among the ineligible patients. Mortality was fivefold higher among ineligible patients (19%; Cl, 16% to 21%) than among protocol-treated patients (4%; Cl, 1% to 6%) (P less than 0.001). In-hospital mortality rates for excluded patients were 28% (Cl, 23% to 32%) in elderly patients (age, greater than 76 years; n = 396); 29% (Cl, 23% to 35%) in patients with stroke or bleeding risk (n = 209); 17% (Cl, 14% to 20%) in patients with delayed presentation (greater than 4 hours after the onset of chest pain; [n = 599]); 14% (Cl, 11% to 16%) in patients with an ineligible electrocardiogram (ECG) (n = 673); and 26% (Cl, 21% to 32%) in patients with a miscellaneous reason for exclusion (n = 243). Independent predictors of increased mortality were: age greater than 76 years, stroke or other bleeding risk, ineligible ECG, or the presence of two or more exclusion criteria. Thrombolytic therapy is currently used in the United States for only a minority of patients with acute myocardial infarction: those who have low-risk prognostic characteristics.Keywords
This publication has 20 references indexed in Scilit:
- Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implicationsThe American Journal of Cardiology, 1990
- Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- ELIGIBILITY FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1987
- Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinaseThe American Journal of Cardiology, 1987
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- A Prospective Randomized Clinical Trial of Intracoronary Streptokinase versus Coronary Angioplasty for Acute Myocardial InfarctionNew England Journal of Medicine, 1986
- Acute myocardial infarction treated with intracoronary streptokinase: A report of the society for cardiac angiographyThe American Journal of Cardiology, 1985
- Hemorrhage and the products of fibrinogen digestion after intracoronary administration of streptokinase.Circulation, 1984
- Intracoronary streptokinase in clinical practiceAmerican Heart Journal, 1982